Literature DB >> 18829795

Prophylactic phenobarbital administration after resolution of neonatal seizures: survey of current practice.

Ronnie Guillet1, Jennifer M Kwon.   

Abstract

OBJECTIVE: Child neurologists and neonatologists often discharge newborn infants with phenobarbital treatment for weeks to months despite the absence of continuing seizure activity. We conducted a national survey to determine the degree of variation in this practice.
METHODS: Surveys were sent to a randomly generated list of board-certified child neurologists (N = 609) and neonatologists (N = 579). The survey consisted of 3 parts, that is, questions related to overall attitudes and practices, specific patient scenarios, and respondent demographic characteristics. Responses were tabulated and analyzed for all respondents combined and for child neurologists and neonatologists separately. Variation in practices between respondents and the consistency between the respondents' stated use of phenobarbital in practice and their answers to various clinical scenarios were evaluated.
RESULTS: Responses were received from 118 child neurologists (20.7%) and 125 neonatologists (23.1%). There was wide variation in practices, with little difference in the response frequencies between child neurologists and neonatologists. Physicians were more likely to respond yes to continuation of phenobarbital treatment in a given clinical situation than would be predicted on the basis of their answers regarding overall frequency of use.
CONCLUSIONS: Since the survey of practices 15 years ago, child neurologists and neonatologists are reporting less frequent and shorter phenobarbital treatment after resolution of neonatal seizures, although there remains considerable variation in practices. Moreover, what physicians report as their practice in general is inconsistent with how they respond to specific clinical cases of neonatal seizures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829795     DOI: 10.1542/peds.2007-3278

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trial.

Authors:  Jennifer M Kwon; Ronnie Guillet; Seetha Shankaran; Abbot R Laptook; Scott A McDonald; Richard A Ehrenkranz; Jon E Tyson; T Michael O'Shea; Ronald N Goldberg; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Rosemary D Higgins; Michele C Walsh
Journal:  J Child Neurol       Date:  2010-10-04       Impact factor: 1.987

2.  Risk of later seizure after perinatal arterial ischemic stroke: a prospective cohort study.

Authors:  Courtney J Wusthoff; Sudha Kilaru Kessler; Arastoo Vossough; Rebecca Ichord; Sarah Zelonis; Aviva Halperin; Danielle Gordon; Gray Vargas; Daniel J Licht; Sabrina E Smith
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

3.  Treatment Duration After Acute Symptomatic Seizures in Neonates: A Multicenter Cohort Study.

Authors:  Renée A Shellhaas; Taeun Chang; Courtney J Wusthoff; Janet S Soul; Shavonne L Massey; Catherine J Chu; M Roberta Cilio; Sonia L Bonifacio; Nicholas S Abend; Tammy N Tsuchida; Hannah C Glass
Journal:  J Pediatr       Date:  2016-11-07       Impact factor: 4.406

4.  Neonatal Neurocritical Care Service Is Associated With Decreased Administration of Seizure Medication.

Authors:  Sharon O Wietstock; Sonia L Bonifacio; Charles E McCulloch; Michael W Kuzniewicz; Hannah C Glass
Journal:  J Child Neurol       Date:  2014-11-07       Impact factor: 1.987

5.  Continuous Video Electroencephalographic (EEG) Monitoring for Electrographic Seizure Diagnosis in Neonates: A Single-Center Study.

Authors:  S O Wietstock; S L Bonifacio; J E Sullivan; K B Nash; H C Glass
Journal:  J Child Neurol       Date:  2015-06-30       Impact factor: 1.987

Review 6.  Neonatal seizures: advances in mechanisms and management.

Authors:  Hannah C Glass
Journal:  Clin Perinatol       Date:  2013-12-12       Impact factor: 3.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.